Conceivable Life Sciences: Company Profile

Background

Conceivable Life Sciences is a biotechnology company dedicated to revolutionizing fertility care through the automation of in vitro fertilization (IVF) laboratories. By integrating artificial intelligence (AI) and robotics, Conceivable aims to make IVF more accessible, affordable, and effective, addressing the global challenge of infertility. The company's mission is to help more people achieve the dream of becoming parents by transforming the traditional, manual IVF process into a precise, scalable, and cost-effective solution.

Key Strategic Focus

Conceivable's strategic focus centers on the development and commercialization of the world's first AI-powered automated IVF lab, known as AURA. This platform automates over 200 intricate steps involved in embryo creation, including delicate single-cell procedures like intracytoplasmic sperm injection (ICSI). By leveraging AI, robotics, advanced optics, and machine vision, AURA aims to enhance precision, traceability, and scalability in IVF processes. The company targets the global fertility market, addressing the significant unmet demand for IVF services by reducing costs and improving clinical outcomes.

Financials and Funding

As of January 2025, Conceivable Life Sciences has raised over $39 million in funding. The most recent funding round, an $18 million Series A led by ARTIS Ventures, included participation from new investors such as Atlantic Health Venture Studio, Muse Capital, and Scrub Capital, alongside existing investors like ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, and Time BioVentures. The funds are allocated to support ongoing commercial pilot programs and preparations for a U.S. launch targeted for early 2026.

Pipeline Development

Conceivable is currently conducting a 100-patient Institutional Review Board (IRB) study as part of its commercial pilot program in Mexico City. In a prior IRB-approved proof-of-concept study using AURA prototypes, 21 pregnancies were achieved, demonstrating success rates comparable to top-performing fertility clinics. These studies are critical steps toward validating the efficacy and safety of the automated IVF platform ahead of broader commercialization.

Technological Platform and Innovation

Conceivable's AURA platform represents a significant technological advancement in the field of reproductive medicine. Key innovations include:

Proprietary Technologies: AURA integrates six automated workstations that perform all essential IVF lab functions, such as dish preparation, sperm processing, egg discovery and preparation, ICSI, incubation, vitrification, and thawing.

Scientific Methods: The platform employs advanced optics and machine vision to perform precise single-cell surgeries, enhancing the accuracy and consistency of procedures like ICSI.

AI-Driven Capabilities: AI algorithms are utilized for tasks such as sperm selection and embryo classification, aiming to improve success rates and reduce human error.

Leadership Team

Conceivable's leadership comprises a multidisciplinary team with extensive experience in embryology, automation, AI, and robotics:

Alan Murray: Co-founder and Chief Executive Officer, bringing a background in leading innovative startups.

Joshua Abram: Co-founder and Chairman, with a history of successful ventures across various industries.

Dr. Alejandro Chavez-Badiola: Co-founder and Chief Medical Officer, a reproductive endocrinologist instrumental in developing the company's medical technologies.

Dr. Jacques Cohen: Chief Scientific Officer, renowned for his contributions to embryology and reproductive science.

Dr. Stephanie Kuku: Chief Knowledge Officer, overseeing the integration of scientific research and clinical practice.

Ann Watson: Chief Marketing Officer, leading the company's marketing and communication strategies.

The leadership team is supported by experts in engineering, data science, and product development, collectively driving Conceivable's mission forward.

Competitor Profile

Market Insights and Dynamics

The global fertility market is experiencing significant growth, driven by increasing infertility rates and advancements in reproductive technologies. Despite this growth, access to IVF remains limited due to high costs and the manual nature of existing processes. Conceivable's automation technology positions it to address these challenges by offering scalable and cost-effective solutions.

Competitor Analysis

Key competitors in the fertility technology space include:

TMRW Life Sciences: Specializes in automated cryostorage solutions for eggs and embryos, focusing on improving the safety and efficiency of specimen storage.

OvaScience: Develops novel fertility treatments aimed at enhancing egg health and improving IVF outcomes.

Kindbody: Provides comprehensive fertility services, integrating clinical care with technology to enhance patient experience and outcomes.

While these companies contribute to advancements in fertility care, Conceivable's end-to-end automation of the IVF lab distinguishes it by addressing the entire laboratory process, potentially offering greater scalability and cost reductions.

Strategic Collaborations and Partnerships

Conceivable has established partnerships with leading venture capital firms and healthcare investors, including ARTIS Ventures, ACME Capital, and Atlantic Health Venture Studio. These collaborations provide not only financial support but also strategic guidance and industry expertise, bolstering the company's efforts to innovate and expand its market presence.

Operational Insights

By automating the IVF lab, Conceivable aims to achieve several operational advantages:

Precision: Automation reduces human error, enhancing the accuracy of delicate procedures.

Traceability: Digital tracking of specimens ensures safety and accountability throughout the IVF process.

Scalability: Automated systems can handle increased volumes, addressing the growing demand for IVF services.

Cost Reduction: Operational efficiencies lead to lower costs, making IVF more accessible to a broader population.

Strategic Opportunities and Future Directions

Conceivable is poised to capitalize on several strategic opportunities:

U.S. Market Entry: Preparations are underway for a U.S. launch in early 2026, expanding the company's reach and impact.

Technology Refinement: Ongoing research and development efforts aim to further enhance the AURA platform's capabilities and success rates.

Global Expansion: Beyond the U.S., Conceivable plans to introduce its technology to other international markets, addressing the global need for accessible fertility treatments.

Collaborative Research: Partnerships with academic and clinical institutions will support continuous innovation and validation of the company's technologies.